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Abstract
Background: Transcription factor PU.1, a member of the ETS family, is a master regulator of myeloid differentiation
whose functional disruption is often associated with acute myeloid leukemia (AML). Although much has been
learned about PU.1 over the past decades, relatively little is known about cis-elements that interact with this factor
under physiological or pathological conditions, especially in the whole-genome scale. We aimed to define the
cistrome of PU.1 in acute promyelocytic leukemia (APL) cells and characterize the cis-elements bound by PU.1.
Methods: Chromatin immunoprecipitation with specific antibody coupled with deep sequencing (ChIP-seq) was
used to investigate the in vivo PU.1 binding sites at the whole-genome scale in APL-derived NB4 cells. The ChIP-
quantitative (q)-PCR and luciferase reporter assays were used to validate the binding events and trans-activity,
respectively. Various computational analyses, including motif mining, evolutionary conservation analysis and
functional enrichment analysis, were performed to characterize the cis-elements that interacted with PU.1.
Results: A total of 26,907 significantly enriched binding regions of PU.1 were identified under the false discovery
rate 0.1% in NB4 cells. PU.1 bound to various types of genomic regions and acted as a promoter-enhancer dual
binding transcription factor. Based on the sequence length and composition, two types of representative motifs
were identified in PU.1 binding sites: a long and a short motif. The long motif, characterized by high sequence
specificity and binding affinity, predominantly resided in the promoter-distal regions. In contrast, the short one, with
strong evolutionary constraint, represented the primary PU.1 cis-elements in the promoter-proximal regions.
Interestingly, the short one showed more preference to be correlated with the binding of other factors, especially
PML/RARα. Moreover, genes targeted by both PU.1 and PML/RARα were significantly involved in categories
associated with oncogenesis, hematopoiesis and the pathogenesis of acute myeloid leukemia.
Conclusions: Our results demonstrate that structurally differentiated cis-elements that interact with PU.1 are
functionally distinguishable in APL, suggesting that the sequence diversity of cis-elements might be a critical
mechanism by which cells interpret the genome, and contribute to distinct physiological and/or pathological
function.
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Biological processes are orchestrated by precise temporal
and spatial regulation of gene expression, requiring proper
interactions between cis-regulatory elements and trans-
acting factors (TFs). Disruption of such interactions often
causes disease. Over the past decades, much has been
learned about actions of TFs under various physiological or
pathological conditions, whereas relatively little is known
about the cis-elements that control TF-specific gene ex-
pression [1]. Recent advances in genomic technologies, in-
cluding chromatin immunoprecipitation coupled with deep
sequencing (ChIP-seq), have allowed the genome-wide
recognition of in vivo cis-trans interacting sites, thus
facilitating the survey of structural and functional features
of thousands of cis-elements simultaneously, and providing
the opportunity to understand the mechanism of gene
regulation in a more comprehensive manner.
In hematopoiesis, a number of master TFs which play
major instructive roles for hematopoietic development or
malignant transformation have been identified and inten-
sively studied. PU.1, one of these master TFs, is exclusively
expressed in hematopoietic cells and has been identified
as a crucial transcription factor in normal hematopoiesis
and in generation of myeloid leukemia through disruption
of its function [2]. In acute promyelocytic leukemia (APL),
a subtype of AML with the typical promyelocytic leukemia-
retinoic acid receptor α (PML/RARα) fusion protein in
the disease cells, PU.1 is expressed at reduced levels and
increased expression mediated by gene transfer of PU.1 is
sufficient to induce neutrophil differentiation, similar to
the effect of all-trans retinoid acid (ATRA) [3,4]. With
transgenic mouse models, the penetrance rate of APL
development is significantly increased in offspring when
PML/RARα mice are crossed with PU.1
+/- mice [5]. These
observations collectively suggested the presence of cross-
talk between PU.1 and PML/RARα in APL. Using ChIP
combined with whole-genome promoter arrays, we previ-
ously investigated the early molecular effects of PML/
RARα in hematopoietic progenitor cells and demonstrated
that PML/RARα disrupts the PU.1 regulated genes and
thus results in a blockage of the downstream PU.1 signa-
ling [6]. However, a question regarding whether cis-elements
that interact with PU.1 contribute to the selective binding of
PML/RARα in APL remains unknown.
It is interesting to note that myeloid specific genes such
as granulocyte colony-stimulating factor (G-CSF) receptor
[7], granulocyte-macrophage (GM)-CSF receptor α [8]
and macrophage (M)-CSF receptor [9] have PU.1 binding
sites in their promoter regions. However, as these genes
are investigated at the single-gene level, it is challenging to
gain a comprehensive understanding of the cis-elements
that are essential for the regulation of myeloid-specific
genes. For instance, PU.1 was first reported to bind to
purine-rich 5
0-GGAA/T-3
0 sequences, similar to other
members of the Ets family [10,11]. However, later studies
showed that the DNA binding specificity of PU.1 was
quite different from that of the other members, in that
some sites required a string of adenosine residues at the 5
0
of the GA core [8,9,12,13]. Additional data indicated that
some of the PU.1 binding sites were biologically significant
but lack of the adenosine string at the 5
0 of GA core [14].
Also, nucleotides (i.e., G and T) flanking the 3
0 end of the
GAGGAA sequence appear to be important for PU.1
binding and its transactivation activity [15]. Given the
reported variability of PU.1 binding sites, and our interest
in this transcription factor in disease, we performed ChIP-
seq experiments in the APL-derived NB4 cells using PU.1-
specific antibody to identify the in vivo PU.1 binding sites
at the whole-genome scale. This revealed a number of
interesting features which are potentially important for
regulating myeloid differentiation and leukemogenesis.
Results
Identificationand validation ofin vivo bindingregions of PU.1
Chromatin immunoprecipitation (ChIP) with PU.1-specific
antibody followed by deep sequencing was performed
for the APL-derived NB4 cells. As shown in Table 1, a total
of 15.6 million 35-bp sequence reads were generated, of
which 11.8 million (76%) were aligned uniquely and non-
redundantly to the human genome (HG18). Based on the
false discovery rate (FDR) of 0.1%, a total of 26,907 signifi-
cantly enriched ChIP regions with a median length of 429
bp were identified (Table 1, Additional file 1: Figure S1 and
Additional file 2: Table S1) through MACS [16]. Figure 1A
illustrates a representative chromatin region (6p21.33),
showing enriched peaks of PU.1 binding. As shown in
Figure 1A and Additional file 3: Figure S2, sharp enrich-
ment peaks were found in proximal or/and distal regions
of promoters for previously reported PU.1 target genes (e.
g., BTK [17], CSF1R [9], CSF2RB [18], ITGAM [12], NCF2
[19] and NCF4 [20]), and novel target genes of PU.1,
such as NFKBIL1, LST1 and AIF1.A sav a l i d a t i o n ,C h I P -
quantitative(q)-PCR was then conducted on the binding
regions of 8 previously known targets, 9 randomly selected
de novo targets and 4 negative controls (Figure 1B), sho-
wing results consistent with those of ChIP-seq in this se-
tting. Since PU.1 primarily is considered as a transactivator
in myeloid differentiation [21], we then selected eight
enriched regions on a random basis and applied them to
luciferase assays in 293T cells (Figure 1C). Clearly, PU.1
transactivated these regions, adding further evidence that
the ChIP regions identified in this setting represent bona
fide functional binding sites of PU.1 in APL cells.
Characterizing PU.1 as a promoter-enhancer dual binding
TF
In an attempt to identify potential features associated with
PU.1 binding sites, we first compared binding locations to
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RefSeq Database [22], and found that 14.1% (3,804/
26,907) of the binding sites mapped to the promoter
regions, 41.9% (11,271/26,907) to the intragenic regions
(gene body) and 44.0% (11,832/26,907) to the interge-
nic regions (including 16.5% upstream enhancers, 9.9%
downstream enhancers and 17.5% distal intergenic re-
gions) (Figure 2A), as classified by the recommended
criteria (see Materials and methods). These results indi-
cate that the binding spectrum of PU.1 is highly complex
and versatile in APL cells. Next, we conducted sequence
evolutionary conservation analysis across 27 vertebrate
genomes on each of the mapped sections. As shown in
Figure 2B, the summit of PU.1 enriched binding regions
revealed higher evolutionary conservation than the flan-
king regions, implicating the biological relevance of PU.1
binding. Moreover, the highest conservation scores were
obtained with the promoter-proximal binding sites, sup-
porting the notion that cis-elements in promoter regions
are evolutionally conserved [23]. In contrast, the PU.1
promoter-distal binding sites (including those in the intra-
genic and intergenic regions) revealed relatively low con-
servation scores, consistent with the idea that cis-elements
in enhancers or other distal regulatory elements are rela-
tively dynamic among species [24].
Next, we performed a correlation analysis between the
PU.1 binding sites versus total gene number and nucleo-
tide number on each chromosome, respectively. As a con-
trol, we conducted the same analysis with the binding
sites of a classic promoter-binding factor RNA polymerase
II (RNAPII), a typical enhancer-binding protein estrogen
Table 1 ChIP-seq reads and peaks threshold at
FDR=0.001
Parameter NB4 PU.1
Reads Total sequenced (millions) 15.6
Total, mapped (millions) 14.8
Total, uniquely mapped
and Non-redundant (millions)
11.8
In peaks (millions) 1.44 (12.1%)
Peak coverage (Mb) 13.1 (0.5%)
Median width (bp) 429
Enrichment 25.01
Peaks Number of peaks 26,907
Minimum fold enrichment 3.68
Average fold enrichment 32.92
Median fold enrichment 26.45
Notes: Peak coverage percentages assume a 2.7 Gb genome.
Figure 1 Identification and validation of PU.1 binding regions. (A) The visual representation of PU.1 targets on Chromosome 6 (chr6) partial
regions identified through ChIP-seq analysis. The red and black tracks represent the ChIP-seq tag density of the sample (PU.1) and control (Input),
respectively. (B) Validation of the PU.1 binding regions by ChIP-qPCR assays. Corresponding RefSeq genes for individual binding regions are
marked underneath. Special codes “P”“ E”“ S”“ L” inside the brackets, representing promoter, enhancer, short transcript and long transcript, were
used to distinguish the regions corresponding to the same gene. (C) Luciferase reporter assays on representatives of PU.1 target genes (NCF4,
NCF2, IL1B, BTK, PTPRC, NTS, RGS18, and CD1163) reporter plasmids and expression plasmids were co-transfected into 293T cells.
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[26], STAT1 [27], FOXA1 [28], GATA1 [29] and GATA2
[30] (Figure 2C and Additional file 4: Table S2), whose
genome-wide binding sites have been documented previ-
ously. Interestingly, the PU.1 binding sites were correlated
with both the chromosomal gene number (r
2=0.70) and
nucleotide number (r
2=0.72) (Figure 2C), which appeared
to be distinguishable from most of the other tested factors
except for STAT1, a known promoter-enhancer dual bind-
ing TF [31,32]. The factors like RNAPII, CTCF, GATA1
and GATA2, were obviously correlated with the number
of genes, whereas those like ER and FOXA1, known as
two specific enhancer-binding proteins, were correlated
with the number of nucleotides. The above observations
suggest that PU.1 may act as a versatile factor able to
interact with cis-elements not only in promoter regions
but also in enhancer regions.
In addition, we investigated the PU.1 binding locations
and numbers on their corresponding RefSeq genes
(9,556), revealing that 33.3% (3,184/9,556) of the RefSeq
genes harbored the binding sites on their promoter-
proximal regions whereas 66.7% (6,372/9,556) contained
the binding sites on the promoter-distal regions. These
observations, together with data shown in Figure 2A,
suggest that promoter-distal binding of PU.1 may play
at least as equally important roles as the promoter-
proximal binding in transcriptional regulation. Interest-
ingly, more than half of the genes (1,598/3,184) with
promoter-proximal binding of PU.1 appeared to contain
additional binding sites in their promoter-distal regions,
suggesting that PU.1 regulatory mechanisms can be far
more complex than previously recognized, by involving
multiple trans-cis interaction sites. This would allow for
precise control of gene expression that is essential for
myeloid differentiation. Indeed, auto-regulation of the
PU.1-encoding gene SPI1 appears to require PU.1 bin-
ding at both the promoter [21] and enhancer (i.e., 17 kb
upstream) [33]. In this study, we found in addition to
the sites reported previously two additional sites were
identified 9.6 kb and 14.6 kb upstream of the gene
(Figure 2D). An additional example is the integrin alpha
M chain (CD11b) gene, ITGAM. This gene is known to
Figure 2 Characterization of identified PU.1 binding regions. (A) Pie diagram showing distribution of PU.1 binding regions located in the
proximal promoter (within 2 kb 5
0 and 1kb 3
0 to the TSS), gene body (+1kb of TSS to transcription end site, TES), upstream enhancer (between at
most -50 kb and -2 kb from TSS), downstream enhancer (from TES to at most 50 kb downstream), or distal intergenic regions (more than 50 kb
to TSS and TES). (B) Evolutionary conservation analysis of each genomic type of PU.1 binding regions used multiple alignments of 27 vertebrate
genomes with human. All the regions are aligned at peak summits in a 5
0-to-3
0 manner. (C) Correlation of the binding sites of PU.1, STAT1, ER,
FOXA1, RNAPII, CTCF, GATA1 and GATA2 with each chromosome, ranked according to total gene number and total nucleotide number.
(D) Representative PU.1 target genes identified through ChIP-seq analysis. (Arrows) ChIP-seq peak locations relative to the transcription start site
of the respective PU.1 target gene (kb).
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cytes during differentiation. It contains one PU.1 binding
site at the promoter as previously reported [12]. In our
study we have identified another site 16 kb upstream
of the gene, representing a potential enhancer region
(Figure 2D). Such structures may typically represent PU.1-
involved trans-cis interactions required for myeloid diffe-
rentiation. In consistent with this notion, numerous other
myeloid differentiation-required genes are also multi-
targeted by PU.1, such as LMO2, BCL3, IL1B and IL12B
(Figure 2D and Additional file 5: Figure S3).
Distinct features of the short and long motifs in the PU.1-
bound regions
To identify cis-elements that interact with PU.1 in the
enriched binding regions, we conducted motif discovery
analysis using several discovery tools, including (1) the de
novo motif discovery methods AMD [34] and MEME [35],
and (2) the prior-compiled PSFM-based motifs detection
method termed MotifScan (see Materials and methods).
Based on sequences corresponding to the top 500 most-
enriched binding regions, two types of motifs appeared to
be repeatedly observed in a significant manner (Figure 3A).
O n ei sc o n t a i n e di nt h ed a t a b a s eo fT R A N F A Ca n dk n o w n
as the canonical PU.1 consensus sequence of 5
0-AG(A/G)
GGAAG-3
0 (left panel) and the other is found by de novo
scanning, with a motif sequence of 5
0-(A/G)AAAG(A/G)
GGAAGTG-3
0 (right panel and Additional file 6: Figure
S4). This de novo motif covers the canonical one but identi-
fies additional preferences including adenine at the -3 to -1
position, and thymine and guanine at the +1 and +2 posi-
tions. For convenience, we have named the motif including
5
0 adenines as “long motif” and the canonical one as “short
motif”.
Next, we scanned the total binding regions of PU.1
using the above long and short motifs by MotifScan. As
shown in Figure 3B, 37.1% of the binding regions con-
tained one or more long motifs, and 46.3% of the binding
regions contained only the short motif. The remaining
16.6% revealed neither long nor short motifs, which were
likely due to undetected PU.1-binding motifs present in
these regions, or due to the possibility that for these sites
PU.1 does not directly bind to chromatin, but rather forms
a complex through protein-protein interactions. Positional
distribution analysis revealed that both motifs, especially
the long one, appeared to reside near the center of the
binding regions (Figure 3C). We then evaluated the bind-
ing affinities of the long and short motifs by comparing
their enrichment levels. As shown in Figure 3D, the long
motif exhibited a much higher mean tag density than the
short one, particularly with respect to the tag density in
the regions (-100 to +100) flanking the summit of peaks.
Consistently, we found that the higher the enrichment
levels, the more (less) the percentages of the long (short)
motifs (Figure 3E). These observations suggest that the
long motif exhibits higher binding affinity to PU.1 than
the short one. Interestingly, sequence evolutionary conser-
vation analysis showed that the binding sites with the
short motif appeared to be much more conserved than
the long motif-containing sites (Figure 3F). These results
together suggest that the motif preference may correlate
with the motif location in the genome, implicating that
functional roles played by the two types of motifs can be
different in general. Then, we examined the proportional
distributions of the short or long motifs in promoter re-
gions vs. non-promoter regions, respectively. As shown in
Figure 3G, the percentage of short or long motifs (48.8%
vs. 36.1%, outer circle) in non-promoter regions was
equivalent to that for the total of PU.1 binding sites
(46.3% vs. 37.1%, Figure 3B), whereas, that in the pro-
moter regions with 63.3% short motifs and 14.5% long
motifs (inner circle) was significantly different from that.
In sum, cis-elements that interact with PU.1 can be clas-
sified into short and long motif classes based on their
sequence patterns. In promoter regions, PU.1-cis elements
are predominantly represented by those in the class of
short motif, which are highly conserved across species
but with lower binding affinity to PU.1. In contrast,
cis-elements in the class of long motif are relatively de-
pleted from promoter regions whereas primarily present
in non-promoter regions, representing PU.1 binding sites
of high affinity but evolutionally less conserved.
Short motif-containing binding regions of PU.1
preferentially targeted by other factors including PML/RARα
We previously demonstrated that PML/RARα selectively
targets PU.1 binding regions that harbored both PU.1
binding sites and RARE (retinoic acid response element)
half (RAREh) sites [6]. In the present study, we found
that cis-elements that interact with PU.1 could be distin-
guished by the sequence length and composition, evolu-
tionary conservation, genomic distribution and binding
affinity. A remaining question would be whether these
motifs were functionally differentiated, e.g., in the genesis
of APL. In an attempt to answer this question, we exam-
ined PU.1 binding sites in the genomic regions targeted by
PML/RARα. First, ChIP-seq was performed using specific
antibodies against PML and RARα respectively, and a total
of 3,551 highly significant (FDR < 0.01) PML/RARα bin-
ding sites were identified (Additional file 7: Table S3).
When the binding sites of PML/RARα and those of PU.1
were compared, over 53% (1,886/3,551) of the PML/RARα
were also targeted by PU.1 (Figure 4A). When short and
long elements of PU.1 motifs were respectively compared
in the PU.1-specific binding sites, and PU.1 and PML/
RARα overlapping binding sites (PU.1&PR), we observed
dramatic differences (Figure 4B). For the PU.1&PR set, al-
most 70% of the sites were represented by the short PU.1
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In contrast, the proportion in the PU.1-specific set was
49.5% long and 34.7% short. These results indicated that
the short motif elements are strongly correlated with the
selective targeting of PU.1 binding sites by PML/RARα
whereas the long motif elements are largely depleted from
such a targeting. Although much remains to be elucidated,
our results, at least, suggest that binding of PU.1 to short
motif elements may offer this factor a selective preference
to recruit PML/RARα. Previously, we have shown that
PU.1 is able to direct the binding of PML/RARα to nearby
RARE half (RAREh) sites at the level of promoters [6]. We
thus extended this analysis to a whole genome scale and
analyzed the enrichment of RAREh sites in the three
subpopulations (PU.1-specific, PU.1&PR and PR-specific).
As illustrated in Figure 4C, RAREh sites were significantly
enriched in the PR-specific (Z-score = 22.3) and PU.1&PR
(Z-score = 21.4) sets, whereas the RAREh sites were rela-
tively depleted from the PU.1-specific set (Z-score = 3.35).
This result further indicates that the selective binding of
PML/RARα to PU.1 binding sites requires both RAREh
and short consensus elements of PU.1.
Figure 3 Identification and characterization of enriched motifs within PU.1 binding regions. (A) Sequence logos were shown for
significant PU.1 motifs. The logo on the left was generated with V$PU.1_Q6 PSFM from TRANSFAC database, where the logo on the right was
obtained by de novo motif finding using AMD. (B) Percentages of the PU.1 binding regions with the long motif (green) or the short motif only
(orange). These two colors were consistently used to indicate the two specific sub regions in the following figure parts, respectively.
(C) Histogram representing the distribution of the long PU.1 motif and only the short one within the PU.1 binding regions relative to the summit
of the binding regions (represented as 0). (D) Comparison of tag density between the PU.1 binding regions with the long motif and only the
short one. (E) Comparison of percentage of PU.1 binding sites between the long motif-containing and only the short motif-containing along the
mean of peak fold enrichment. (F) Conservation analysis of PU.1 binding regions with the long motif or the short one used multiple alignments
of 27 vertebrate genomes with Human. All of the regions are aligned at peak summits in a 5
0-to-3
0 manner. (G) Proportions of the long and only
short motif-containing PU.1 binding sites from the promoter (inner circle) or non-promoter (outer circle) regions showed with annular charts. The
proportion of neither the long nor short motif-containing PU.1 binding regions was indicated with the gray color.
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regions with distinct cis-elements could be co-bound or
tethered differentially by other factors in addition to PML/
RARα. For this analysis we took advantage of the pub-
lished Encyclopedia of DNA elements (ENCODE) project
data that includes the genomic regions bound by 119 hu-
man transcription factors involving 72 different cell types
[36,37]. We compiled three different PU.1-bound region
sets, including the PU.1-specific with the long motif
(Long), the PU.1-specific with the short motif (Short) and
the PU.1&PR, and carried out overlapping analysis with
1328 ChIP-seq data sets downloaded from the UCSC EN-
CODE data center. As shown in Figure 4D and 4E, most
of the ENCODE TFs showed significantly less preference
to the Long set than the Short set and the PU.1&PR
set (paired t-test p<1e-303 and p<1e-296, respectively). In
particular, factors, such as MAX (21.3% vs. 37.7%) and
MYC (17.8% vs. 34.4%) in NB4 cells, JUND in K562 cells
(13.4% vs. 26.0%) and CTCF in HCPE (12.3% vs. 27.3%)
and HBMEC (12.9% vs. 25.9%) cells showed the most dis-
tinct overlapping percentage between the Long and Short
sets. In contrast, the Long set was significantly more cov-
ered by 9 ENCODE PU.1 data sets involving 4 cell types
(GM12878, GM12891, HL60 and K562) than the Short
and PU.1&PR sets (paired t-test p<1e-6 and p<0.0002,
respectively; Figure 4F). The result suggested that the
long-motif-containing sites kept more PU.1 binding stabil-
ity among different cell types, consistent with their higher
binding affinity to PU.1 revealed above, while the short-
motif-containing sites could recruit more TFs to regulate
the corresponding gene expression.
Furthermore, we wanted to know whether genes re-
gulated by different PU.1 cis-elements or binding factors
were functionally differentiated. Thus, we conducted Gene
Ontology (GO) and Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway analyses respectively on the
three gene sets (Long, Short and PU.1&PR). As shown in
Figure 4G, the most striking GO terms revealed in
the gene set targeted by both PU.1 and PML/RARα
(PU.1&PR) were highlighted by genes involved in onco-
genesis and hematopoiesis. The former was represented
by JUNB, BCL2, MLLT10, FES, FOS and MCL1, and the
latter was represented by RUNX1, CEBPA and STAT3.
Similarly, the most significant KEGG pathways revealed in
this gene set were represented by those involved in acute
myeloid leukemia, including SPI1, RARA, KRAS and so on
(Figure 4H and Additional file 8: Figure S5). These results
provide additional evidence that genes targeted by both
PU.1 and PML/RARα are indispensable for the normal
hematopoiesis, and are crucial for leukemogenesis (Figure
4G and 4H). Besides, we also noticed that the genes belong
to the Long set specifically evolved in several biological
processes and functional pathways, such as developmental
processes and adherens junction, respectively. The Short
gene set, however, showed little particularly functional
enrichment, implying PU.1 may involve more extensive
biological functions rather than some specific ones through
the different dynamic combinations with other factors.
Discussion
PU.1 is a master TF in myeloid differentiation, regulating
numerous myeloid genes involved in hematopoiesis. Under-
standing cis-regulatory elements that interact with PU.1 may
provide insights into regulatory networks underlying mye-
loid differentiation and related diseases. In this study, we
identified 26,907 in vivo PU.1 binding sites in APL-derived
NB4 cells by ChIP-seq. Through various analyses, we found
the PU.1 binding sites were primarily represented by two
types of cis-elements. One, with high sequence specificity
and binding affinity, resides primarily in the promoter-distal
regions, and a second, with strong evolutionary constraint,
represents the primary PU.1 cis-elements in the promoter-
proximalregions;thelattertendtobeboundbyPU.1inasso-
ciation with other factors such as PML/RARα,M Y Ca n d
MAX. Our findings suggest that sequence diversity of TF
binding cis-elements is a critical mechanism by which cells
interpret the genome, and contribute to distinct physio-
logical and/or pathologicalfunction.
(See figure on previous page.)
Figure 4 PU.1 binding sites with short motif selectively targeted by other factors including PML/RARα. (A) Venn diagram displaying the
overlap of PU.1 binding regions and PML/RARα binding regions in NB4 cells. (B) Schematic illustration of the PU.1 motif comparison between
PU.1 binding regions and PML/RARα binding regions. PU.1-specific is the subpopulation of PU.1 binding regions that do not overlap with PML/
RARα binding regions. PU.1&PR is the subpopulation of PU.1 binding regions that overlap with PML/RARα binding regions. The color bars
indicate the percentages of the regions with the long, only short PU.1 motif and neither, with green, orange and gray, respectively. (C) Bar plot of
Motif RARE half (RAREh) enrichment in three subpopulations. PU.1-specific and PU.1&PR mean the same as above. PR-specific is the
subpopulation of PML/RARα binding regions that do not overlap with PU.1 binding regions. (D) Scatter plot showing the covered percentages of
PU.1-specific binding sites with the long motif versus that with the short motif by ENCODE ChIP-seq data sets of transcription factors except PU.1.
(E and F) Box plot of the covered percentages in three PU.1 binding sets, including PU.1&PR, Long and Short, by ENCODE ChIP-seq data sets of
PU.1 and other factors, respectively. The “Long” represents the PU.1-specific binding set with the long motif, while the “Short” represents those
only with the short motif. The differences between the two binding sets were assessed using the paired t-test. The p-values are shown in the
panels. (G and H) Heat map of functional enrichment with the items of PANTHER gene ontology in biological process and KEGG pathways. The
enrichment level (-10*log10 (p-value)) was indicated with red color. The “PU.1&PR”, “Long” and “Short” represent the corresponding gene sets to
the sets of binding sites defined above.
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regions separated by hundreds of kilobases is thought to
be important in the regulation of gene expression [38].
By analyzing the distribution of PU.1 binding sites in
APL, we found that over 85% of the sites resided in
chromatin regions away from promoters. Interestingly,
after mapping the PU.1 binding sites to the known
RefSeq genes, more than half of the promoter-targeted
RefSeq genes (1,598/3,184) contained additional PU.1
binding site at non-promoter regions, suggesting the
presence of complex networks of interconnected chro-
matin. Also, it is tempting to assume that there is a
mode of action through the long-range regulation in
addition to conventional models of the promoter regula-
tion in PU.1-regulated gene expression. Such an assump-
tion appears to be supported by recent findings in many
cell types, in which long-range interactions are common
for transcriptional regulation [39], and by the findings
that interacting loci between transcription start sites
(TSSs) and enhancers are strongly correlated with gene
expression level [36]. Another example of long-range
regulation is provided by estrogen receptor alpha (ERα)
induced looping [40], in which the vast majority of ERα
binding sites reside in non-promoter regions [41]. It has
been reported that PU.1 mediated looping between pro-
moter pIII and the distal element termed hypersensitive
site 1 (HSS1) of transcriptional co-activator CIITA in B
cell of mouse model [42], but whether looping is com-
mon or infrequent in the regulatory networks of PU.1
remains to be elucidated. Consistent with previous in-
vestigations at the single gene level, our study added
additional 1,598 PU.1 target genes potentially regulated
across long distances.
The availability of genome-wide TF binding sites bene-
fits our investigation regarding the regulatory mechanisms
underlying protein-DNA interaction and improves the ac-
curacy for analyzing cis-regulatory elements. In this study,
we found potential cis-elements of PU.1 target genes can
be classified into the canonical short consensus (AG(A/G)
GGAAG) and the extended long consensus ((A/G)AAAG
(A/G)GGAAGTG). The shorter sequence appears to be
highly conserved across species but shows less binding af-
finity to PU.1, whereas the extended one demonstrates
high binding affinity but low evolutionary conservation.
This observation is also supported by a microarray-based
binding affinity study, in which the vast majority of the
104 DNA-binding proteins tested showed different bind-
ing affinities to different DNA consensuses [43]. Interest-
ingly, potential cis-elements in the promoter-proximal
regions of PU.1 regulated genes are predominantly repre-
sented by the short motif elements (63.4%) whereas these
regions are relatively depleted of the long motif elements
(14.5%). In contrast, the long motif elements primarily res-
ide in the promoter-distal regions (including enhancers).
Although it remains to be elucidated why these long and
evolutionally diverse elements are predominantly located in
non-promoter regions, it might be of interests to speculate
that these elements may play species-specific roles in pre-
cise regulation of gene expression required for myeloid.
Of note, PML/RARα targeted PU.1 binding regions are
highly enriched with the canonical short consensus
(69.2%) but depleted of the extended long consensus se-
quence (11.6%). An intensive overlapping analysis revealed
that most of the over 100 tested transcription factors
showed more preference to the short-motif-containing
binding regions of PU.1. Although much remains to be
elucidated, it is tempting to assume that binding of PU.1
to the low affinity canonical consensus may represent
an important mechanism that controls physiological or
pathological process through the differential dynamic
combinations with other factors, such as MYC and MAX.
The extended long consensus elements are mostly distrib-
uted in non-promoter regions, and represent high affinity
binding sites of PU.1. We speculate that these sites co-
operate with the binding sites in promoter regions and
regulate hematopoietic specific genes through long-range
regulation. In the presence of the pathological protein
PML/RARα, these sites are devoid of targeting by PML/
RARα to a large extent, probably needed to keep certain ex-
pression levels of the genes. Indeed, 80% down-regulation
of PU.1 in hematopoietic cells causes the blockage of cell
differentiation [44] and resto r a t i o no fP U . 1e x p r e s s i o ni n -
duces neutrophil maturation [3]. Obviously, much remains
to be investigated about regulatory networks of PU.1 in
myeloid differentiation or leukemogenesis. However, find-
ings and a resource of thousands of potential cis-elements
of PU.1 from this setting may facilitate such investigation in
a more effective and efficient manner.
Conclusions
We here describe a genome-wide characterization of
in vivo binding sites of PU.1 in APL-derived NB4 cells.
Our results demonstrate that PU.1 can regulate target
genes by binding to both the promoter-proximal and
distal cis-elements. Moreover, we reveal that structurally
differentiated cis-elements that interact with PU.1 are func-
tionally distinguishable in acute promyelocytic leukemia,
suggesting that sequence diversity of cis-elements that
interact with trans-acting factors might be a critical mech-
anism by which cells interpret the genome, and contribute
to distinct physiological and/or pathological function.
Materials and methods
Cell culture
NB4 cells were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS). HEK
293T cells were cultured in Dulbecco’s modified Eagle’s
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midified atmosphere with 5% CO2 at 37°C.
Plasmid construction, cell transfection and luciferase
reporter assays
Promoter and enhancer regions harboring PU.1 motifs
were cloned into the pGL3-basic and pGL3-promoter vec-
tor (Promega, Madison, WI), respectively. The primers
used for the plasmids constructs are listed in Additional
file 9: Table S4. The renilla luciferase plasmid pRL-SV40
(Promega, Madison, WI) was used as control for trans-
fection efficiency. The expression plasmid was pCMV4-
PU.1. HEK 293T cells were transiently transfected using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Transfected
cells were cultured for 48 hours and then assayed for luci-
ferase activity using Dual-Luciferase Reporter Assay System
reagents (Promega, Madison, WI).
ChIP-qPCR
ChIP-qPCR was performed using Power SYBR
W Green
PCR Master Mix (Applied Biosystems, Foster City, CA)
and ABI Prism 7900HT detection system (Applied Bio-
systems, Foster City, CA). The fold enrichment of the
tested binding regions over the input DNA was estimated
as previously described [45]. The primers used for ChIP-
q P C Ra r el i s t e di nA d d i t i o n a lf i l e1 0 :T a b l eS 5 .
ChIP-seq and data analysis
ChIP was performed using specific antibodies according
to the Affymetrix protocol as described previously [40].
ChIPed and Input DNA were sequenced with Illumina
Genome Analyzer II. The 35 bp reads (or tags) were
aligned (mapped) to the unmasked human reference gen-
ome (NCBI v36, hg18) using the Eland application
(Illumina) allowing two mismatches. Only uniquely mapped
reads were retained to further analyses. Next, MACS [16]
algorithm was used to identify PU.1 binding regions. For
the visualization of the enrichment level of transcription
factor’s binding sites, we calculated the tag density of each
ChIP-seq sample with 500 bp window, aligned it to the
same coordinate and visualizedt h e mi nab a rp l o tu s i n gt h e
IGB (Affymetrix) program.
Peak mapping and annotation
We used the RefSeq Genes’ database from UCSC to map
and annotate the peak regions. For each peak region, we
first searched the nearest RefSeq gene in both directions
unless no gene was found within 50 kb. For a peak
region lying within a gene, we classified it to the prox-
imal promoter (-2 kb upstream to 1kb downstream to
TSS), gene body (1 kb downstream of the TSS to the
transcription end site (TES)), upstream enhancer (be-
tween at most -50 kb and -2 kb upstream to the TSS), or
downstream enhancer (from TES to at most 50 kb
downstream). Otherwise, we marked these peaks as dis-
tal intergenic region (>50 kb from a RefSeq gene). To
avoid multiple genomic region type annotation of one
peak, we uniquely mapped the peaks to genomic region
type following the priority rule: proximal promoter > gene
body > upstream enhancer > downstream enhancer > distal
intergenic region.
Sequence evolutionary conservation analysis
The enriched peaks were first uniquely mapped to cer-
tain genomic regions according to the above peak map-
ping and annotation criteria. Then, the regions were
aligned at their summits from 5
0 to 3
0 in accordance with
the orientation of the corresponding genes (if a peak be-
longs to the distal intergenic region, we arbitrarily as-
sume that the peak is on the positive strand) and
uniformly expanded to 3,000bp in each direction, and
phastCons scores were retrieved from UCSC genome
browser (http://genome.ucsc.edu) and averaged at each
position.
Statistical analysis of the known motifs with MotifScan
A position-specific frequency matrix (PSFM) similarity
based motif analysis algorithm, named MotifScan, was
used to analyze the enrichment of the known motifs statis-
tically on the ChIP-seq data. Fold enrichment and Z-score
were used to assess the significance of motif enrichment.
MotifScan was performed as follow:
1) The acquisition of motif PSFM
The motif PSFM can be from the result of de novo
motif analysis on a set of DNA sequence data. In
this study, the long motif PSFM of PU.1 was from
the result of AMD [34], an automated motif
discovery tool using stepwise refinement of gapped
consensuses, analysis on the highly enriched PU.1
occupancy sites of ChIP-seq data set. It also could
be from some motif information database directly
and the TRANSFAC database was used in this study.
2) The calculation of similarity between a motif and a
DNA sequence
Given a motif with length l bp, the similarity (S) for
a DNA sequence with equal length was calculated as
follow:
S ¼
X l
j¼1
Ij 2
ﬃﬃﬃﬃﬃ
Pij
p
  1
  
X l
j¼1
Ij 2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
P max
j
q
  1
  
Where Ij indicates the information content of the
motif j-th column, Pij is the frequency of a particular
letter i in the j-th column and P max
j is the frequency
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column. Details described as follow:
Ij ¼
X
i∈ A;T;G;C fg
Pij log
Pij
Qi
0
@
1
A
Where:
  Pij – The frequency of a particular letter i in the
j-th column (i. e. if G occurred 3 out of 6 times
in an alignment column, this would be 0.5). We
define Pij log Pij = 0, when Pij =0 .
  Qi – The expected frequency of a letter i. This is
an optional argument, usage of which is left at
the user’s discretion. By default, it is automatically
assigned to 0.25 = 1/4 for a nucleic acid alphabet.
This is for getting the information content
without any assumption of prior distributions.
3) The computation of fold enrichment (F) and Z-
score (Z)
For a specific motif, the sequence with a similarity higher
than the threshold was marked as a matched sequence.
Suppose that the total number of matched sequences was
X in a data set with total effective sequence length L bp
(repeat masked). Then the random variable X followed the
binomial distribution with parameters n and p, written as
X∼B(n,p), where n≈L,a n dp was the possibility that each
bp contained a matched sequence. In this case, n was very
large generally. Meanwhile, n*p and n*(1-p) were large
enough. Thus, to simplify the calculation, we used the nor-
mal distribution X∼N(np,np(1−p)) to excellently approxi-
mate the binomial distribution. Subsequently, we further
simplified the 1–p as 1, since the p was small generally.
Therefore, the expected value (E) and the variance (σ
2)o f
X would be the same.
Next, the total number of matched sequences was
counted in a background data set and a sample data set,
respectively. Suppose that the total number of matched
sequences is Ns in a sample data set with total effective
sequence length Ls (bp), and Nc in a background data set
with total effective sequence Lc (bp). We calculated the
expected number of matched sequences in the sample
data set as E ¼
Nc Ls
Lc Followed the above simplified for-
mula, the fold enrichment and Z-score were calculated
as F ¼ Ns=E and Z ¼ Ns E ﬃﬃ ﬃ
E
p , respectively.
Percentage calculation of the motif-containing peaks
For a specific motif, if a peak region contained at least
one matched sequence, then we marked this peak as a
motif-containing one. The percentage of certain motif-
containing peaks was calculated as the number of motif-
containing ones divided by all the number of peaks. The
similarity was calculated as the same as in MotifScan
algorithm. In this study, to enhance the accuracy and
specificity, the similarity threshold for the “long” PU.1
motif was set at 0.8 and that for the “short” PU.1 motif
and RARE half was set at 0.9. We first excluded all the
long PU.1 motif-containing peaks when calculating the
only short PU.1 motif-containing ones, as the short PU.1
motif was nearly covered by the long one.
Additional files
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on different FDR levels.
Additional file 2: Table S1. Significantly enriched PU.1 ChIP regions in
NB4 cells.
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identified through ChIP-seq analysis.
Additional file 4: Table S2. Chromosomal distribution of PU.1 binding
sites.
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discovery method MEME.
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